Figure 3

ROC curve analysis in the discovery, validation and combined cohorts comparing the ability of the miRNA signature to identify prostate cancer patients. (a) A combined measure of the sensitivity and specificity of the miRNA signature in the discovery cohort (N = 61) is represented by the Area under the curve AUC = 0.82 (p < 0.0001, 95% CI = 0.72–0.93). (b) A combined measure of the sensitivity and specificity of the miRNA signature in the validation cohort (N = 58) is represented by AUC = 0.95 (p < 0.0001, 95% CI = 0.89–1.00). (c) A combined measure of the sensitivity and specificity of the miRNA signature in a combined cohort (N = 119) is represented by AUC = 0.88 (p < 0.0001, 95% CI = 0.82–0.94). The diagonal reference line reflects the performance of the diagnostic test i.e. whether a test yields the positive or negative results by chance or due to a relation with the true disease status.